on VALBIOTIS (EPA:ALVAL)
Valbiotis to present at American Diabetes Association sessions
The French biotechnology company Valbiotis has been selected to present its clinical results at the 84th scientific sessions of the American Diabetes Association. The event will be held from June 21 to 24, 2024.
The studies concern TOTUM•63, an innovative and 100% plant-based food supplement, intended for the treatment of prediabetes and type 2 diabetes. This work was carried out as part of Phase II/III REVERSE-IT and in collaboration with several research institutes.
Professor Samy Hadjadj underlined the importance of the results obtained, in particular the reduction in glycated hemoglobin, a crucial marker of diabetes. In addition, a study on the mode of action of TOTUM•63 will also be presented.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news